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Abstract
Background: Schizophrenia and bipolar disorder are severe mental illnesses which are highly prevalent worldwide.
Risperidone and Paliperidone are treatments for either illnesses, but their efficacy compared to other antipsychotics
and growing reports of hormonal imbalances continue to raise concerns. As existing evidence on both
antipsychotics are solely based on aggregate data, we aimed to assess the benefits and harms of Risperidone and
Paliperidone in the treatment of patients with schizophrenia or bipolar disorder, using individual participant data
(IPD), clinical study reports (CSRs) and publicly available sources (journal publications and trial registries).
Methods: We searched MEDLINE, Central, EMBASE and PsycINFO until December 2020 for randomised placebo-
controlled trials of Risperidone, Paliperidone or Paliperidone palmitate in patients with schizophrenia or bipolar
disorder. We obtained IPD and CSRs from the Yale University Open Data Access project. The primary outcome
Positive and Negative Syndrome Scale (PANSS) score was analysed using one-stage IPD meta-analysis. Random-
effect meta-analysis of harm outcomes involved methods for coping with rare events. Effect-sizes were compared
across all available data sources using the ratio of means or relative risk. We registered our review on PROSPERO,
CRD42019140556.
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Results: Of the 35 studies, IPD meta-analysis involving 22 (63%) studies showed a significant clinical reduction in the
PANSS in patients receiving Risperidone (mean difference − 5.83, 95% CI − 10.79 to − 0.87, I2 = 8.5%, n = 4 studies,
1131 participants), Paliperidone (− 6.01, 95% CI − 8.7 to − 3.32, I2 = 4.3%, n = 13, 3821) and Paliperidone palmitate
(− 7.89, 95% CI − 12.1 to − 3.69, I2 = 2.9%, n = 5, 2209). CSRs reported nearly two times more adverse events (4434 vs.
2296 publication, relative difference (RD) = 1.93, 95% CI 1.86 to 2.00) and almost 8 times more serious adverse events
(650 vs. 82; RD = 7.93, 95% CI 6.32 to 9.95) than the journal publications. Meta-analyses of individual harms from CSRs
revealed a significant increased risk among several outcomes including extrapyramidal disorder, tardive dyskinesia and
increased weight. But the ratio of relative risk between the different data sources was not significant. Three treatment-
related gynecomastia events occurred, and these were considered mild to moderate in severity.
Conclusion: IPD meta-analysis conclude that Risperidone and Paliperidone antipsychotics had a small beneficial effect
on reducing PANSS score over 9 weeks, which is more conservative than estimates from reviews based on journal
publications. CSRs also contained significantly more data on harms that were unavailable in journal publications or trial
registries. Sharing of IPD and CSRs are necessary when performing meta-analysis on the efficacy and safety of
antipsychotics.
Keywords: Antipsychotics, Risperidone, Paliperidone, Schizophrenia, Bipolar disorder, Individual participant data, Meta-
analysis, Clinical study reports
Background
Schizophrenia and bipolar disorder are highly prevalent
and debilitating severe mental illnesses worldwide. Pa-
tients often experience both simultaneously because they
share a similar causative process of diagnoses [1].
Risperidone is a leading second-generation anti-
psychotic drug approved for the treatment of schizo-
phrenia in adults and adolescents and for the short-term
treatment of manic or mixed episodes of bipolar dis-
order [2, 3]. It is indexed on the World Health Organiza-
tion’s List of Essential Medicines as one of the most
effective and safe medicines [4]. However, the manufac-
turers ‘Johnson & Johnson’ have been involved in over
13,500 legal (lawsuit) cases because of their failure to
disclose that Risperidone may cause hormonal imbal-
ances that could lead to breast tissue development
(‘gynecomastia’) and increased blood prolactin levels
(‘galactorrhoea hyperprolactinaemia’) in boys and girls
[5, 6]. There have also been ‘black box warnings’ of mis-
leading marketing of the drug for off label uses in chil-
dren and adolescents with schizophrenia or bipolar
disorder and in elderly patients with dementia [7, 8].
Moreover, the clinical benefit of Risperidone is question-
able when compared to other antipsychotics and was re-
cently found to be only the sixth best treatment option
for overall change in symptoms of schizophrenia [9, 10].
Paliperidone is another second-generation anti-
psychotic drug also manufactured by Johnson & Johnson
and used to treat schizophrenia. As both Risperidone
and Paliperidone act via the same pathways in the body,
research have suggested strong links of drug-induced
hormonal imbalances in both antipsychotics [11], and
like Risperidone, the efficacy of Paliperidone over other
antipsychotics is also questionable [10]. Other serious
adverse events experienced by patients with severe men-
tal illnesses receiving either Risperidone or Paliperidone
include muscle-related ‘extrapyramidal effects’; perman-
ent movement disorders such as ‘tardive dyskinesia’;
cerebrovascular events including stroke, transient ischae-
mic attack, vascular malformation and venous thrombo-
embolism [12, 13]; and neuroleptic malignant syndrome,
increased risk of suicide and weight gain [14, 15]. How-
ever, these harms are rarely reported exhaustively in
journal publications.
The existing evidence that support policy on both
antipsychotic drugs is solely based on aggregate data
meta-analyses of published randomised controlled tri-
als (RCTs) involving mostly adults [16]. Analyses of
more exhaustive forms of unpublished data including
individual participant data (IPD) and clinical study re-
ports (CSRs) are increasingly recommended for evalu-
ating the full evidence base for the effectiveness and
safety of these drugs. Such analyses can create clear
hierarchies of evidence about the benefit and harms
of both interventions, taking into account reporting
bias, and have the potential to better inform policy
decisions.
The Yale University Open Data (YODA) project was
setup to promote better transparency of clinical trial re-
sults. As of 2014, YODA have been enabling scientists
across the world to gain access to Johnson & Johnsons
clinical trial data assets including Risperidone and Pali-
peridone [17–19]. Using more innovative methodologies
on a hitherto unavailable and more complete database
from IPD and CSRs contained in YODA, we aim to
compare in a meta-analysis the benefit and harms of
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Risperidone and Paliperidone with data from corre-
sponding trial register entries and journal publications.
Methods
The study followed a registered (PROSPERO CRD42019140556
[20]) protocol and findings are reported in accordance
with the PRISMA-IPD statement [21].
Search methods
Searches were done from inception until December
2020 without language restriction in the MEDLINE
(Ovid), Cochrane Central Register of Controlled Trials,
EMBASE (EBSCO) and PsycINFO (see searches in Add-
itional file 1: Table S1). Key terms used in the searches
were intervention-related (Risperidone, Risperdal, Ris-
perdal Consta, Paliperidone, Invega, Trevicta and
Xeplion) and condition-related (schizophrenia, psych-
osis, psychotic, bipolar disorder and cyclothymic dis-
order). The number of citations identified varied
between database with EMBASE identifying 361 cita-
tions and MEDLINE 51 citations. Trial registers includ-
ing ClinicalTrials.gov, the WHO ICTRP portal and
OpenTrials.net and drug approval packages at the Food
and Drug Administration [22] and European Product
Assessment Reports [23] were searched for further
studies.
Eligibility
We included randomised placebo-controlled trials in-
volving patients diagnosed with schizophrenia or bipolar
disorder.
Interventions include Risperidone (brand name: Ris-
perdal (oral) and Risperdal Consta (intravenously
injected)), Paliperidone (brand name: Invega and Tre-
victa) or Paliperidone palmitate (brand name: Xeplion)
with any form of application at any dose. As the in-
cluded trials were placebo-controlled, the comparator
was therefore a placebo pill or kit vials which contained
microspheres with no active drug.
The primary outcome for efficacy includes the Positive
and Negative Syndrome Scale (PANSS) total score com-
prising the three subscales positive, negative and general
psychopathology which are regarded as the ‘gold stand-
ard’ for assessment of psychotic behaviour disorders. We
used a 30-point subtraction to calculate the PANSS total
score which is important for interpreting the percentage
change of improvement in the mental health state of the
patients [24]. Based on previous recommendations [25],
we categorised the difference in PANSS from baseline
using following improvement thresholds: 25% (minimal
improvement), 50% (good clinical response) and 75%.
Secondary outcomes for efficacy include the mean time
after treatment until relapse, Clinical Global Impression-
Severity (CGI-S) scale and the Young Mania Rating
Scale (YMRS).
For safety, primary outcomes include treatment-
emergent adverse events (AEs), serious adverse events
(SAEs) following the Food and Drug Administration’s
definition (including life-threatening, hospitalisation, dis-
ability or permanent damage, congenital anomaly/birth
defect, required intervention to prevent permanent im-
pairment or damage or other serious important medical
events), discontinuations due to AE, gynecomastia and
drug-induced death. Secondary outcomes include cere-
brovascular events, extrapyramidal disorder, weight in-
creased, tardive dyskinesia and behaviour-related
outcomes (i.e., aggression, irritability and intentional
self-injury). These outcomes were informed by previous
meta-analyses [10, 26–28], patient and public involve-
ment feedback and black box warnings [29].
Data collection, extraction and risk of bias
A research application was made for IPD and CSRs of
each of the publications identified at YODA [30]. We
were able to access another trial [31] upon request
which was not listed on their website; but trials not
sponsored by Johnson & Johnson could not be provided
[32–34]. Further requests for CSRs were made at the
European Medicines Agency for the two centrally li-
cenced antipsychotics Paliperidone and Paliperidone
palmitate. We were successful in retrieving two CSRs
[35, 36] for Paliperidone at the European Medicines
Agency clinical data website [37]. But, because of an on-
going court case about public access to clinical trial data
from 2019 to 2020 [38, 39], this meant that we were un-
able to obtain access to further trial CSRs.
Data extractions were conducted by two independent
reviewers (AH, MP). Discrepancies were resolved
through consensus or recourse to a third reviewer (EK).
For each matching document pair (CSR, Registry report
and Journal publication) supplemented by the IPD; the
study characteristics, content and a comparison of
reporting were done using the criteria as outlined in
Additional file 2: Table S2. Risk of bias for each study
was assessed by two reviewers (AH, MP) using the
Cochrane Risk of Bias (RoB) tool [40]. In each domain,
the scores of the RoB assessment reflected all the avail-
able evidence and thus allowed for downgrading of RoB
by considering any new evidence available from the cor-
responding CSR that are not reported in the journal
publication.
Data synthesis
In this comparison, pooled estimates for all outcomes of
interest were compared across the three data sources
(CSR, trial registry and journal publication) to assess for
consistency. The pooled effects from each data source
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were then compared using the ‘ratio of relative risks’ or
‘ratio of means’ to observe for statistical differences [41].
For the primary efficacy outcome (PANSS), IPD-MAs
effect-sizes were included also in the ratio of mean com-
parisons. In total, sixty-one possible outcome-specific
meta-analysis comparisons were made enabling compar-
isons of the pooled effects from the different data
sources.
Aggregate data from CSRs, journal publication and
registry reports were meta-analysed using DerSimonian-
Laird random-effects [42]. For continuous outcomes,
standardised mean differences (SMD) were calculated
using Hedges’ g [43] and interpreted according to
Cohen’s criteria [44]. Hartung-Knapp confidence inter-
vals were used to account for uncertainty in the variance
estimate [45]. For dichotomous outcomes (including
AEs), effects were assessed by pooling the relative risk
(RR). Effect estimates were pooled across trials using
Mantel Haenszel fixed-effect or inverse-variance
random-effects meta-analysis dependent upon the num-
ber of studies reporting the outcome of interest. A sensi-
tivity analysis was also performed pooling the relative
difference instead of RR for rare events [46, 47]. For
studies reporting single or double zero events in one or
both treatment group, we used the ‘exact’ fixed-effect
meta-analysis method for pooling the effects [48]. Safety
narratives were also obtained from the listings data
where possible.
We then performed the one-stage IPD meta-analysis
for the primary outcome PANSS total score [49, 50].
Scores were adjusted ensuring zero as the lowest pos-
sible score [51]. Meta-analysis of the non-standardised
PANSS total score was used as the primary measure to
assess the percentage reduction change for clinical im-
provement. Missing data were imputed using the R
package ‘MICE: Multivariate Imputation by Chained
Equations’ following Rubin’s rules [52]. The imputed
values used observed values of the primary outcome
PANSS and baseline covariates (study, interventions,
age, gender and baseline PANSS score) to predict miss-
ing data. Convergence of the algorithms was assessed,
and sensitivity analyses were performed using only cases
with available data.
The analyses used ‘one-stage’ linear mixed effect
models which incorporated random-effects to allow for
heterogeneity across trials [50, 53, 54], fitted using Stata
(software version 16.1) [55] command mixed and the
ipdforest command to summarise the evidence by study
and obtain forest plots [56]. Restricted maximum likeli-
hood was used for model estimation and centring of co-
variates by study-specific means was performed to avoid
aggregation bias [57]. Differential effects were investi-
gated by adding covariate parameters (age, gender and
ethnicity) and interactions between covariate (treatment-
covariate interaction terms) and antipsychotic treatment
to the linear mixed model [58].
We used the I2 statistic to determine the magnitude of
heterogeneity and associated 95% confidence intervals
(CIs) [59, 60]. Effects across different type of severe
mental illness and dosage regiments (approved accord-
ing to the national US [29, 61, 62] and EU guidelines
[63, 64] vs. other doses) were assessed in subgroup ana-
lyses. Sensitivity analysis of the effects of just including
low RoB studies was performed for the PANSS outcome.
Patient and public involvement
A group of 31 partners who were members of an estab-
lished patient and public involvement group were con-
sulted about the appropriateness of our research
questions, and selection of the outcome measures of this
study. A patient representative provided input to the in-
terpretation and writing up of results. The dissemination
plan targets a wide audience, including members of the
public, patients, health professionals and experts in the
specialty through various channels: written communica-
tion, events and conferences, networks and social media.
Results
A total of 1288 references were retrieved. Following full-
text screening of 204 studies, 57 RCTs met our inclusion
criteria and IPD/CSRs were accessible for 35 (61%) stud-
ies involving 12,316 patients (Fig. 1). The characteristics
of the 35 studies are provided in Additional file 3: Table
S3 [31, 35, 36, 66–96]. The remaining 22 studies were
excluded due to their low quality, differences in primary
outcome selection with only a single subscale being used
to measure PANSS and a general poor reporting of
harms meaning data could not be include in the meta-
analysis.
Characteristics of included studies
Twenty-five studies (71%) were carried out in America
and seven (20%) in Europe. The median number of pa-
tients across the studies was 323 (IQR, 263). The median
age across studies was 39 (IQR, 4) years, and only three
studies (9%) [66, 67, 97] involved children or adolescents
under the age of 19 years. Twenty-eight of the studies
(80%) involved more male patients than female.
Twenty-five (71%) of the studies involved patients with
schizophrenia, and 10 (29%) involved patients with bipo-
lar disorder. Paliperidone was administered in sixteen
(46%) of the studies comprising 4920 participants, eleven
studies (31%; 3697 participants) used Risperidone (six in-
volving oral administered Risperidone and five intraven-
ous administration of Risperidone Consta) and eight
studies (23%; 3699 participants) used Paliperidone
palmitate. Oral and intravenously administered Risperi-
done were combined into one analysis due to the limited
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number of studies available in the IPD meta-analysis.
The median length of the intervention was 63 (IQR, 53)
days. The doses used for oral administration of Risperi-
done and Paliperidone ranged from 1 to 75 mg and for
long-acting injectable Paliperidone palmitate, 25 to 150
mg.
Description of data
Full IPD data including demographic, efficacy and safety
listings data were available for 34 (97%) of the studies.
The 35 CSRs comprised of a median 825 (IQR, 548)
pages (Additional file 4: Table S4). Statistical analysis
plans and protocols were provided separately for 32
(91%) of the CSRs. A low level of redactions in the CSRs
(i.e. subject ID and investigator names) were found in
only three of the studies [67–69], 29 studies presented
with a medium level of redactions (i.e. narratives
removed from the appendix) and three [70, 71, 98] had a
high level of redactions (i.e. pages removed from the
core report and/or some outcome data were redacted)
(Additional file 5: Table S5). Only adverse events with
over 5% incidence in any treatment group were reported
in 22 of the CSRs (63%), and the remaining 13 (37%)
studies reported only AEs with over 2% incidence.
Quality assessment of the studies
Risk of bias assessment of the studies involving all data
sources combined, is shown in Additional file 6: Table
S6. For Risperidone, one study had overall high RoB,
four had a moderate RoB and six with low RoB. For Pali-
peridone, two studies scored with a high RoB, five with
moderate RoB and 10 with low RoB. Seven Paliperidone
palmitate studies scored with low RoB and only one
study scored with a moderate RoB. The domain for
Fig. 1 PRISMA flowchart of search strategy showing trials identified through literature search and previous meta-analyses, trial registers and
through correspondence with YODA and regulators. RCTs, randomised controlled trials; EMA, European Medicines Agency; FDA, Food and Drug
Administration; WHO, World Health Organisation; YODA, Yale Open Data Access. Asterisk indicates [27]; phi symbol, [28]; beta symbol, [65]; and
Yen symbol [10]
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‘Blinding of participants and personnel’ had the greatest
number of studies (n = 4) at high risk. CSRs were re-
sponsible for downgrading individual high-risk study do-
mains to low on 36% of occasions.
Comparison of reporting of design factors and outcomes
between sources at study level
Compared to the trial register entries and journal publi-
cations, the CSRs reported on average more design fac-
tors including randomisation (86% vs. 0% vs. 64%,
respectively), allocation concealment (80% vs. 3% vs.
33%) and blinding (100% vs. 6% vs. 58%) (Table 1). Sam-
ple size determination was reported in 91% of CSRs,
compared to 52% of journal publications and 3% of
registry reports.
Primary and secondary outcomes were reported with
100% consistency in the CSRs, 88% and 85% in the regis-
try reports and 76% and 61% in the journal publications.
Clear narratives for deaths were reported in 88% of jour-
nal publications compared to CSRs. Reporting of AEs
was poor in registry reports with only 29% of studies
providing amenable/extractable data. Reporting of SAEs
was also poor in both journal publications and registry
reports, with only 61% and 49% of studies providing
data. In contrast AEs and SAEs were reported more
clearly in the CSRs of each study, as were
discontinuations.
Data synthesis of efficacy outcomes
IPD meta-analysis involving 7161 patients from 22 studies
enabling calculation of the PANSS total score, showed a
statistically significant clinical reduction of PANSS in par-
ticipants receiving Risperidone (mean difference − 5.83,
95% CI − 10.79 to − 0.87 [SMD = − 0.29, 95% CI − 0.55 to
− 0.03], I2 = 8.5 (1.6 to 43.2) %, n = 4 studies, 1131 partici-
pants) (Fig. 2a), Paliperidone (− 6.01, − 8.7 to − 3.32
[SMD = − 0.29, 95% CI − 0.40 to − 0.17], I2 = 4.3 (1.5 to
12.1) %, n = 13, 3821) (Fig. 2b) and Paliperidone palmitate
(− 7.89, − 12.1 to − 3.69 [SMD = − 0.35, 95% CI − 0.50 to
− 0.19], I2 = 2.9 (0.4 to 20.2) %, n = 5, 2209) (Fig. 2c). No
significant covariate interactions were found in age,
gender or ethnicity (see Additional file 7: Table S7).
Table 1 Comparison of reporting of design factors, statistical analysis and reporting of efficacy and safety outcomes across all three
data sources
Key information based on reporting of design aspects and








Randomisation 30 (86%) 0 (0%) 21 (64%)
Allocation concealment 28 (80%) 1 (3%) 11 (33%)
Blinding 35 (100%) 2 (6%) 19 (58%)
Sample size calculation 32 (91%) 1 (3%) 17 (52%)
Inclusion criteria specified 35 (100%) 32 (94%) 32 (97%)
Definition of causality provided 30 (86%) 1 (3%) 5 (15%)
Intervention and comparator
Intervention used 35 (100%) 30 (88%) 33 (100%)
Dose and delivery 35 (100%) 10 (29%) 27 (82%)
Placebo pill explained (i.e. visual detail) 27 (77%) 1 (3%) 9 (27%)
Outcomes
Primary outcome specified 35 (100%) 30 (88%) 25 (76%)
Secondary outcomes specified 35 (100%) 29 (85%) 20 (61%)
HRQoL measured (i.e. SQLS or sleep quality) 26 (74%) 3 (9%) 9 (27%)
Symptoms (depression or suicidality) 34 (97%) 1 (3%) 5 (15%)
Safety
AEs 35 (100%) 10 (29%) 29 (88%)
SAEs 35 (100%) 17 (49%) 20 (61%)
Discontinuation due to AEs 33 (94%) 9 (26%) 20 (61%)
Reason for withdrawal 31 (89%) 1 (3%) 11 (33%)
Death 35 (100%) 9 (26%) 29 (88%)
Reason for death 35 (100%) 33 (97%) 30 (91%)
CSR clinical study reports, HRQoL health-related quality of life, SQLS sleep quality of life survey, AEs adverse events, SAEs serious adverse events
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Meta-analyses of the PANSS total score and the sec-
ondary efficacy outcomes in CSR, journal publications
and registry reports were analysed separately and are
provided in Additional file 8: Table S8.
A comparison of the ratio of means for the pooled
PANSS total score across all four data sources are re-
ported in Table 2. No significant differences were ob-
served across all three interventions. Similarly, the effect
measures for the secondary efficacy outcomes led to no
significant differences when comparing the ratios of the
pooled effect estimates between the different data
sources (see Table 3).
Reporting and data synthesis of harm outcomes
The reported harm outcomes across the three different
sources of data are presented in Fig. 3.
AEs were reported nearly twice as often in CSRs com-
pared to journal publications (4434 vs. 2296, showing a
relative difference (RD) = 1.93, 95% CI 1.86 to 2.00) and
by almost six-fold compared to registry reports (4434 vs.
747 showing RD = 5.94, 95% CI 5.54 to 6.36). Similarly,
SAEs were reported almost eight times and five times
more often in CSRs compared to the journal publica-
tions (650/82; RD = 7.93, 95% CI 6.32 to 9.95) and regis-
try reports (650/130; RD = 5, 95% CI 4.16 to 6.02),
respectively. However, the ratio of relative risks for AEs
and SAEs comparing CSRs with journal publications or
registry reports were not significantly different (Add-
itional file 9: Table S9).
Study discontinuations caused by AE (536/258), extra-
pyramidal disorders (461/227) and increase weight (285/
173) were all reported nearly twice as often in the CSRs
compared to journal publications. Drug-induced deaths
and gynecomastia were consistently reported between
CSRs and publications. Reporting rates for all the harm
outcomes are provided at study level in Additional file
10: Fig S1.
Patient safety narratives revealed that the cause of
drug-induced deaths was due to suicide (depression or
overdose), coronary heart disease and stroke. The three
Fig. 2 a One-stage IPD meta-analysis of Risperidone efficacy according to total PANSS. MD, mean difference; 95% CI, 95% confidence interval;
REML, restricted maximum likelihood. b One-stage IPD meta-analysis of Paliperidone efficacy according to total PANSS. MD, mean difference; 95%
CI, 95% confidence interval; REML, restricted maximum likelihood. c One-stage IPD meta-analysis of Paliperidone palmitate efficacy according to
total PANSS. MD, mean difference; 95% CI, 95% confidence interval; REML, restricted maximum likelihood
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Table 2 Ratio of means with 95% CIs of PANSS total scores compared between the four sources of data (individual participant data,
clinical study report, journal publication and registry report)










Risperidone 0.87 (− 0.37,
1.48)
0.21 (− 0.05, 0.68) NA 0.38 (− 0.07, 0.81) NA NA
Paliperidone 0.29 (− 0.02,
0.60)





0.08 (− 0.17, 0.33) 0.21 (− 0.53, 0.95) 0 (− 0.23, 0.23) 0.13 (− 0.22, 0.48) 0.13 (− 0.25, 0.51)
IPD individual participant data, CSR clinical study report, NA not applicable
Table 3 Ratio of risks, odds, difference or means of secondary efficacy outcomes and harm outcomes across the three sources of
data (clinical study report, journal publication and registry report)
Outcomes CSR vs. journal publication CSR vs. registry report Journal publication vs. registry report
Risperidone
Efficacy
Time to relapse ROR = 1.43 (0.31, 6.48) ROR = 1.73 (0.39, 7.65) ROR = 1.21 (0.56, 2.61)
YMRS ROM = − 1.83 (− 4.76, 1.10) ROM = − 2.38 (− 4.64, 0.12) ROM = − 2.38 (− 4.64, 0.12)
CGI-S ROM = − 0.56 (− 3.38, 2.26) NA NA
Safety
TEAEs RRR = 0.97 (0.83, 1.14) RRR = 1.03 (0.86, 1.23) RRR = 1.06 (0.84, 1.33)
SAEs RRR = 0.70 (0.14, 3.42) RRR = 1.48 (0.64, 3.45) RRR = 2.13 (0.37, 12.3)
Discontinuation due to AEs RRR = 1.14 (0.63, 2.05) RRR = 0.65 (0.16, 2.67) RRR = 0.57 (0.14, 2.42)
Death NA NA NA
Paliperidone
Efficacy
Time to relapse ROR = 3.63 (0.33, 39.44) ROR = 0.31 (0.03, 3.84) ROR = 0.09 (0.03, 0.27)
YMRS ROM = 0.96 (− 1.73, 3.65) ROM = − 0.28 (− 1.93, 1.37) ROM = − 1.24 (− 4.16, 1.68)
CGI-S ROM = 2 (− 1.13, 5.13) ROM = − 0.46 (− 1.83, 0.91) ROM = − 2.46 (− 5.52, 0.60)
Safety
TEAEs RRR = 1 (0.91, 1.10) RRR = 0.86 (0.71, 1.03) RRR = 0.86 (0.71, 1.04)
SAEs RRR = 1 (0.61, 1.64) RRR = 1.38 (0.40, 4.84) RRR = 1.38 (0.37, 5.17)
Discontinuation due to AEs RRR = 1 (0.55, 1.80) RRR = 1.04 (0.36, 3.00) RRR = 1.04 (0.37, 2.89)
Death NA NA NA
Paliperidone palmitate
Efficacy
Time to relapse ROR = 1.25 (0.03, 60.54) ROR = 0.17 (0.003, 8.75) ROR = 0.14 (0.06, 0.30)
YMRS NA NA NA
CGI-S NA ROM = 0 (− 0.32, 0.32) NA
Safety
TEAEs RRR = 0.95 (0.79, 1.15) RRR = 0.90 (0.76, 1.07) RRR = 0.95 (0.74, 1.21)
SAEs RRR = 2.54 (0.81, 7.98) RRR = 1.13 (0.62, 2.05) RRR = 0.44 (0.13, 1.47)
Discontinuation due to AEs RRR = 0.88 (0.24, 3.20) RRR = 0.96 (0.47, 1.99) RRR = 1.09 (0.34, 3.45)
Death NA NA NA
ROM ratio of means, RRR ratio of relative risks, ROR ratio of odds ratio, NA not applicable, CSR clinical study report, PANSS Positive and Negative Syndrome Scale,
YMRS Young Mania Rating Scale, CGI-S Clinical Global Impression rating scales, TEAEs treatment-emergent adverse events, SAEs serious adverse events
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cases of gynecomastia in treatment group were reported
only in adults as being probably related to treatment but
were considered mild to moderate in nature (see narra-
tives in Additional file 11: Table S10).
Results of all harm outcomes by each data source
and intervention are presented in Additional file 8:
Table S8. There was a significant increased risk of
extrapyramidal disorders and increased weight in all
three interventions when pooling across the CSRs.
Overall, the risk of an AE increased whilst receiving
Risperidone or Paliperidone. However, the ratio of
relative risks or risk differences of the pooled effects
between the different data sources, showed no signifi-
cant differences (Table 3).
Subgroup analyses
A significant increased risk of AEs, SAEs or extrapyram-
idal disorders was found in schizophrenia diagnosed pa-
tients when pooled across the CSRs (Additional file 12:
Table S11). The pooled effects from journal publications
for these same outcomes did not show an increase in
risk. Risperidone when provided at a dose above 6 mg
showed a significant reduction in PANSS score when
based on data from the journal publications. However,
no significant reduction was found in the pooled effects
using data from the CSRs (Additional file 13: Table S12).
Forest plots for all meta-analysis are provided in Add-
itional file 14: Fig S2. Sensitivity analysis involving only
low risk of bias studies did not reveal any significant
differences in PANSS score (Additional file 15: Fig S3).
Discussion
This meta-analysis presents the most in-depth investiga-
tion to date of the efficacy and safety of Risperidone and
Paliperidone in patients with schizophrenia or bipolar
disorder.
Our IPD meta-analysis showed a significant reduction
in the PANSS total scores for the use of both Risperi-
done and Paliperidone. However, the effects were more
conservative when compared with the results of a recent
network meta-analysis involving both oral forms of in-
terventions compared against placebo (i.e., Risperidone:
SMD = − 0.55 vs. − 0.32; Paliperidone: SMD = − 0.49 vs.
− 0.31) [10]. More importantly, the actual clinical reduc-
tion in the PANSS total score was smaller than the evi-
dence reported in three separate Cochrane reviews
comparing each intervention to placebo (Risperidone
− 17.81 (− 18.17, − 17.45) [27] vs. − 5.83 (− 10.79 to − 0.87);
Paliperidone − 8.99 (− 11.1, − 6.9) [28] vs. − 6.01 (− 8.7 to
− 3.32); Paliperidone palmitate − 8.07 (− 9.75, − 6.39) [65]
vs. − 7.89 (− 12.1 to − 3.69)). Given that our estimates are
based on a similar number of patients, these differences
could be attributed to methodological limitations of these
previous studies compared to our more in-depth and
robust analysis approach. Previous meta-analyses have
relied upon data from published literature of these three
interventions which make them more vulnerable to
reporting biases [99] and are overly reliant on treatment
effects that have been estimated using less robust
methods.
Our most notable finding was the inconsistencies in
the reporting of harms between CSRs and journal
Fig. 3 Display of the total number of events combined over the 35 studies for key safety outcomes by the source of data. See ‘Additional file 11:
Table S10’ for sensitivity analysis for causes of deaths and gynecomastia cases and the forest plots in ‘Additional file 14: Fig S2’ provide the total
pooled relative risks/risk difference estimates. ‘Additional file 9: Table S9’ provides the relative differences in reporting and the ratio of relative risks
for TEAEs and TESAEs. TEAEs, treatment-emergent adverse events; TESAEs, treatment-emergent serious adverse events; AE, adverse event; CSR,
clinical study report
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publications. CSRs provided over double the number of
AEs, and almost eight times more SAEs showing a
significant increase in the relative differences favouring
CSRs. The effect estimates from CSRs which involved
more patients and studies, revealed an increased risk in
the number of AEs and elevated risks for other harms
such as ‘extrapyramidal disorder’, ‘tardive dyskinesia’
and ‘weight increased’.
Limited outcome data were available for
‘gynecomastia’ and ‘cerebrovascular events’. As these are
very rare events with considerable delayed onset in
younger children, it’s likely that they are not well docu-
mented in these short-term randomised trials of only 63
days follow-up [11]. Therefore, we recommend that both
antipsychotics are administered with caution to children
and adolescents until more solid evidence about the
risks of hormonal imbalances and infertility is available
from trials with long term follow-up data.
The combination of IPD and the corresponding CSR
are the most comprehensive and trustworthy source of
Johnson & Johnson trial evidence available to date. How-
ever, a significant limitation of this study is that we were
unable to access all company data and CSRs for 22 fur-
ther eligible trials, which meant that this review was not
entirely systematic and may be subject to selection bias.
We made several requests for CSRs for Paliperidone
trials at the European Medicines Agency, but one on-
going court case [38, 39] meant that they were unable to
provide access to the CSR for seven further trials. Thus,
to alleviate the potential for selection bias, we inspected
the 22 studies and found that 15 of the studies did not
appear to report any of the relevant adverse event’s data
or provide the overall number of adverse events, and the
other 7 studies did not provide amendable ‘arm-level’
data for inclusion in meta-analysis. Furthermore, the
baseline scores for the primary outcome PANSS were
measured using only one of the subscales in 13 of the
studies and therefore the total PANSS score could not
be estimated; the other 9 studies did not provide
amenable PANSS data meaning they could not be meta-
analysed with the IPD.
Another limitation of the study is that we did not com-
pare the effects of all other efficacy outcomes using IPD
and only a subset of AEs that were considered controver-
sial as informed by earlier meta-analyses or previous ‘black
box’ warnings were assessed using the patient safety list-
ings data. Nevertheless, we did compare the PANSS total
score using all available IPD provided, and CSRs conveni-
ently supplemented where IPD for the outcome were un-
available. Moreover, comparing the differences of the
effect-sizes between two different data sources by using
the ratio of means/relative risk when there is clear overlap
of studies and a lack of independence could well lead to
unwieldly results. However, this was the only way to
compare significance between the pooled effects of the
data sources with any real confidence and precision.
The benefits of all three antipsychotics were more con-
servative than reported in the earlier studies restricted to
only publicly available sources (journal publications and
registry reports) [2, 10, 27, 28]. A less than 20% clinical
improvement of Risperidone, Paliperidone and Paliperi-
done palmitate was observed whereas earlier studies
showed between 20 and 50% clinical improvement.
The poor or miss reporting on harms in journal publi-
cations and registry reports was also concerning and dis-
appointing, but it was in line with other findings looking
at different pharmacological treatments [100, 101]. The
pooled estimates from CSRs revealed a significant
increase in risk across several AEs, which signifies the
importance of CSRs and their use in supporting
evidence-based practices. The thresholds for reporting
harms across all sources of data could also be problem-
atic, especially as rare events such as hyperprolactinae-
mia, gynecomastia and cerebrovascular events usually
fall below the 5% or 2.5% incidence threshold which is
often used in these populations and CSRs generally.
Platforms such as the YODA project and the Clinical
Study Data Request [102] where the public can access
IPD and CSRs from the manufacturers remain key and
should be utilised more by systematic reviewers where
possible. However, incorporating these data into system-
atic reviews requires better awareness of where these
data can be sourced and greater resources [103–105]. In
terms of data sourcing, regulatory agencies such as the
European Medicines Agency [37] and Health Canada
[106] have committed to releasing CSRs for trials on
products that are centrally licenced. This will provide
opportunities for investigators to freely access CSRs eas-
ily by ‘click and download’ for newly licenced interven-
tional products. The Food and Drug Administration in
the USA also launched its pilot scheme back in 2018,
which is similar of that of the EMAs clinical trials data
sharing policy. But access still remains largely restricted
with few known cases of anyone accessing trial data/doc-
uments to date [107].
Moreover, in the UK, there exists a current policy drive
towards improving transparency and open access of clin-
ical trial data [108]. In terms of resource and time involve-
ment, the challenge for funders of research grant
applications is deciding where such comprehensive evi-
dence syntheses are likely to make a difference and priori-
tising their funding even though they require greater
resource and time demands. A framework approach
would help support groups grappling with how to respond
to the increasing availability of these new sources of infor-
mation. It would likely even increase the scientific return
on the funder's investment in the trial and most import-
antly the benefits to the public and future patients.
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Calls for improved reporting standards, especially for
harm outcomes in journal publications, continues to be
debated even after the introduction of reporting guidelines
such as the CONSORT harms [100, 109–111]. Many
journals now allow for the publication of segments of de-
identified IPD, redacted sections of CSRs including tables
or narratives of harms alongside the main journal publica-
tion as supplementary online material. However, not all
trials provide these levels of data, and they are still not as
exhaustive as the full CSRs and/or IPD. The development
of a central repository where all available redacted CSRs
can be indexed and uploaded could help to alleviate some
of the challenges associated with accessing and using these
data. Such a development would require full co-operation
and backing from all key stakeholders.
Conclusions
Using IPD from the drug manufacturer, we found that
Risperidone and Paliperidone lead to small clinical
improvements in patients with schizophrenia or bipolar
disorder which are more conservative compared to those
of previous studies based on publicly available data.
CSRs also contained a significantly greater volume of
major harms compared to journal articles and trial regis-
try reports. Our findings clearly support the use of IPD
and CSRs for accurately assessing the efficacy and safety
of antipsychotic drug interventions. For this type of in-
depth analysis, more informed guidance is needed to
help encourage researchers to access and analyse these
data sources in an efficient manner.
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